Epidemiology & Biostatistics: Publications

This is a complete list of publications from all our faculty members. Publications by individual members can be found on their faculty pages. Aslo see, a full list of Epidemiology and Biostatistics Working Paper.


Abernethy AP, Basch E. Clinical cancer informatics: creating pathways for personalized medicine and rapid learning cancer care. Cancer Journal 2011;17:195-196.

Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, Jacobs G, Levin A, Neville D, Kelsen DP, O’Reilly EM. Targeting mutated k-ras in pancreatic adenocarcinoma using an adjuvant vaccine. American Journal of Clinical Oncology 2011;34:321-325.

Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? International Journal of Gynecological Cancer 2011;21:511-516.

Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers AJ, Guillonneau B, Scardino PT, Eastham JA. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. Journal of Urology 2011;185:477-482.

Akin O, Gultekin DH, Vargas HA, Zheng J, Moskowitz C, Pei X, Sperling D, Schwartz LH, Hricak H, Zelefsky MJ. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. European Radiology 2011;21:1970-1978.

Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ. Ten-year outcomes of high-dose intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429-1437.

Allen PJ, Chou J, Janakos M, Strong VE, Coit DG, Brennan MF. Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. Annals of Surgical Oncology 2011;18:636-641.

Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Beesley J, Webb PM, Australian Cancer Study (Ovarian Cancer), Pearce CL, Wu AH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjær SK, Høgdall E, Cramer DW, Terry KL, Garcia-Closas M, Yang H, Lissowska J, Anton-Culver H, Ziogas A, Schildkraut JM, Berchuck A, Pharoah PD, Ovarian Cancer Association Consortium. Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiology Biomarkers and Prevention 2011;20:1028-1031.

Araten DJ, Notaro R, Thaler HT, Kernan N, Boulad F, Castro-Malaspina H, Small T, Scaradavou A, Magnan H, Prockop S, Chaffee S, Gonsky J, Thertulien R, Tarquini R, Luzzatto L. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of 9 patients and a review of the literature. Haematologica 2011;[epub ahead of print].

Artzrouni M, Begg CB, Chabiniok R, Clairambault J, Foss A, Hargrove J, Lee EK, Siggers JH, Tindall M. The first international workshop on the role and impact of mathematics in medicine: a collective account. American Journal of Translational Research 2011;3:492-497.

Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, Schrag D, Basch E. Reliability of adverse symptom event reporting by clinicians. Quality of Life Research 2011;[epub ahead of print].

Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, Shaw M, Li Y, Hay J, Cleeland CS, Scher HI, Breitbart WS, Basch E. Using confirmatory factor analysis to evaluate construct validity of the brief pain inventory (BPI). Journal of Pain Symptom Management 2011;41:558-565.

Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Barker JN. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011;117:3277-3285; quiz 3478.

Bach PB, Doring T, Gesenberg A, Mohring C, Goepel M. Quality of life of patients after retropubic prostatectomy-pre-and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. Health Quality of Life Outcomes 2011;9:93.

Bach PB, Mirkin JN, Luke JJ. Episode-based payment for cancer care: a proposed pilot for Medicare. Health Aff (Millwood) 2011;30:500-509.

Bach PB, Vickers AJ. Do the data support the co-morbidity hypothesis for the prostate, lung, colorectal and ovarian cancer screening trial results? Journal of Clinical Oncology 2011;29:e387; author reply e388-389.

Bach PB. Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening. Journal of the National Cancer Institute 2011;103:1002-1006.

Bach PB. Reduced lung-cancer mortality with CT screening. New England Journal of Medicine 2011;365:2036;author reply 2037-2038.

Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH. Phytoestrogen consumption from food and supplements and epithelial ovarian cancer risk: a population-based case-control study.  BMC Women’s Health 2011;11:40.

Barnett SA, Rusch VW, Zheng J, Park BJ, Rizk NP, Plourde G, Bains MS, Downey RJ, Shen R, Kris MG. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. Journal of Thoracic Oncology 2011;6:1530-1536.

Basch E, Abernethy A. Encouraging clinicians to incorporate longitudinal patient-reported symptoms in routine clinical practice. Journal of Oncology Practice 2011;7:23-25.

Basch E, Abernethy AP, Reeve BB. Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research. Value Health 2011;14:965-966.

Basch E, Abernethy AP. Supporting clinical practice decisions with real-time patient-reported outcomes. Journal of Clinical Oncology 2011;29:954-956.

Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. Journal of the National Cancer Institute 2011;103:1808-1810.

Basch E, Loblaw A, Prestrud A, Oliver TK, Bacher A, Casscells S, Carducci M, Garrels K, Nordquist L, Raghavan D, Singer E, Taplin ME, Virgo K, Winquist E, Somerfield M, Nam RK. Second-line hormonal therapy for castration-resistant prostate cancer: American Society of Clinical Oncology consensus-based clinical practice guideline. Journal of Clinical Oncology 2011 (in press).

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH. American Society of Clinical Oncology clinical practice guideline update on antiemetics. Journal of Clinical Oncology 2011;29:4189-4198.

Basch E, Somerfield M, Partridge A, Schnipper L, Lyman GH. Should cost and comparative value of treatments be considered in clinical practice guidelines? Journal of Oncology Practice 2011;(in press).

Basch EM, Reeve BB, Mitchell SA, Clauser SB, Minasian L, Sit L, Chilukuri R, Baumgartner P, Rogak L, Blauel E, Abernethy AP, Bruner D. Electronic toxicity monitoring and patient-reported outcomes. Cancer Journal 2011;17:231-234.

Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, Michailidou K, Lu J, Rider DN, Palmieri RT, Stutz MD, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Chang-Claude J, Nickels S, Vrieling A, Flesch-Janys D, Wang-Gohrke S, Eilber U, Bogdanova N, Antonenkova N, Runnebaum IB, Dörk T, Goodman MT, Lurie G, Wilkens LR, Matsuno RK, Kiemeney LA, Aben KKH, Marees T, Massuger LFAG, Fridley BL, Vierkant RA, Bandera EV, Olson SH, Orlow I, Rodriguez-Rodriguez L, Cook LS, Le ND, Brooks-Wilson A, Kelemen LE, Campbell I, Gayther SA, Ramus SJ, Gentry-Maharaj A, Menon U, Ahmed S, Baynes C, Pharoah PD, Muir K, Lophatananon A, Chaiwerawattana A, Wiangnon S, Macgregor S, Easton DF, Reddel RR, Goode EL, Chenevix-Trench G. Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One 2011;6:e24987.

Begg CB. A strategy for distinguishing optimal cancer subtypes. International Journal of Cancer 2011;129:931-937.

Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, Iacocca M, Imielinski M, Kalloger S, Karlan BY, Levine DA, Mills GB, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader JS, Sikic BI, Smith-McCune K, Sood AK, Bowtell D, Penny R, Testa JR, Chang K, Dinh HH, Drummond JA, Fowler G, Gunaratne P, Hawes AC, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Santibanez J, Reid JG, Trevino LR, Wu YQ, Wang M, Muzny DM, Wheeler DA, Gibbs RA, Getz G, Lawrence MS, Cibulskis K, Sivachenko AY, Sougnez C, Voet D, Wilkinson J, Bloom T, Ardlie K, Fennell T, Baldwin J, Gabriel S, Lander ES, Ding LL, Fulton RS, Koboldt DC, McLellan MD, Wylie T, Walker J, O'Laughlin M, Dooling DJ, Fulton L, Abbott R, Dees ND, Zhang Q, Kandoth C, Wendl M, Schierding W, Shen D, Harris CC, Schmidt H, Kalicki J, Delehaunty KD, Fronick CC, Demeter R, Cook L, Wallis JW, Lin L, Magrini VJ, Hodges JS, Eldred JM, Smith SM, Pohl CS, Vandin F, Raphael BJ, Weinstock GM, Mardis ER, Wilson RK, Meyerson M, Winckler W, Getz G, Verhaak RG, Carter SL, Mermel CH, Saksena G, Nguyen H, Onofrio RC, Lawrence MS, Hubbard D, Gupta S, Crenshaw A, Ramos AH, Ardlie K, Chin L, Protopopov A, Zhang J, Kim TM, Perna I, Xiao Y, Zhang H, Ren G, Sathiamoorthy N, Park RW, Lee E, Park PJ, Kucherlapati R, Absher M, Waite L, Sherlock G, Brooks JD, Li JZ, Xu J, Myers RM, Laird PW, Cope L, Herman JG, Shen H, Weisenberger DJ, Noushmehr H, Pan F, Triche T Jr, Berman BP, Van Den Berg DJ, Buckley J, Baylin SB, Spellman PT, Purdom E, Neuvial P, Bengtsson H, Jakkula LR, Durinck S, Han J, Dorton S, Marr H, Choi YG, Wang V, Wang NJ, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Gray JW, Levine A, Socci ND, Liang Y, Taylor BS, Schultz N, Borsu L, Lash AE, Brennan C, Viale A, Sander C, Ladanyi M, Hoadley KA, Meng S, Du Y, Shi Y, Li L, Turman YJ, Zang D, Helms EB, Balu S, Zhou X, Wu J, Topal MD, Hayes DN, Perou CM, Getz G, Voet D, Saksena G, Zhang J, Zhang H, Wu CJ, Shukla S, Cibulskis K, Lawrence MS, Sivachenko A, Jing R, Park RW, Liu Y, Park PJ, Noble M, Chin L, Carter H, Kim D, Karchin R, Spellman PT, Purdom E, Neuvial P, Bengtsson H, Durinck S, Han J, Korkola JE, Heiser LM, Cho RJ, Hu Z, Parvin B, Speed TP, Gray JW, Schultz N, Cerami E, Taylor BS, Olshen A, Reva B, Antipin Y, Shen R, Mankoo P, Sheridan R, Ciriello G, Chang WK, Bernanke JA, Borsu L, Levine DA, Ladanyi M, Sander C, Haussler D, Benz CC, Stuart JM, Benz SC, Sanborn JZ, Vaske CJ, Zhu J, Szeto C, Scott GK, Yau C, Hoadley KA, Du Y, Balu S, Hayes DN, Perou CM, Wilkerson MD, Zhang N, Akbani R, Baggerly KA, Yung WK, Mills GB, Weinstein JN, Penny R, Shelton T, Grimm D, Hatfield M, Morris S, Yena P, Rhodes P, Sherman M, Paulauskis J, Millis S, Kahn A, Greene JM, Sfeir R, Jensen MA, Chen J, Whitmore J, Alonso S, Jordan J, Chu A, Zhang J, Barker A, Compton C, Eley G, Ferguson M, Fielding P, Gerhard DS, Myles R, Schaefer C, Mills Shaw KR, Vaught J, Vockley JB, Good PJ, Guyer MS, Ozenberger B, Peterson J, Thomson E. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-615.

Bennett AV, Patrick DL, Bushnell DM, Chiou CF, Diehr P. Comparison of 7-day and repeated 24-h recall of type 2 diabetes. Quality of Life Research 2011;20:769-777.

Bertuccio P, La Vecchia C, Silverman D, Petersen G, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P. Cigar and pipe  smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4), Annals of Oncology 2011;22:1420-1426.

Berwick M, Begg CB, Armstrong BK, Reiner AS, Thomas NE, Cook LS, Orlow I, Kricker A, Marrett LD, Gruber SB, Anton-Culver H, Millikan RC, Gallagher RP, Dwyer T, Rosso S, Kanetsky P, Lee-Taylor J, for the GEM Study Group. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. Journal of Investigational Dermatology 2011;131:2500-2503.

Bickenbach KA, Gönen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Annals of Surgical Oncology 2011;[epub ahead of print].

Blinder VS, Patil S, Thind A, Diamant A, Hudis CA, Basch E, Maly RC. Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer 2011;[epub ahead of print].

Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Scheff RJ, Chuang E, Moore A, Mazumdar M. Employment after a breast cancer diagnosis: a qualitiative study of ethnically diverse urban women. Journal of Community Health 2011;[epub ahead of print].

Boscoe FP, Johnson CJ, Henry KA, Goldberg DW, Shahabi K, Elkin EB, Ballas LK, Cockburn M. Geographic proximity to treatment for early stage breast cancer and likelihood of mastectomy. Breast 2011;20:324-328.

Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji B-T, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao Y-T, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette smoking and pancreatic cancer: an analysis from the international Pancreatic Cancer Case-Control Consortium (PanC4). Annals of Oncology 2011;[epub ahead of print].

Bosl GJ, Patil S. Reply to S. Stenning et al and J. Lipshitz. Journal of Clinical Oncology 2011:4211-4212.

Bosl GJB, Patil SM. Carboplatin in clinical stage I seminoma: too much and too little at the same time. Journal of Clinical Oncology 2011;29:949-952.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics 2011;43:668-672.

Brader P, Abramson SJ, Price AP, Ishill NM, Zabor EC, Moskowitz CS, La Quaglia MP, Ginsberg MS. Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? Journal of Pediatric Surgery 2011;46:729-735.

Brogi E, Murphy CG, Johnson ML, Conlin A, Hsu M, Patil S, Akram M, NehhozinaT, Jhaveri KL, Hudis CA, Seidman AD.  Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of Oncology 2011;22:2597-2603.

Brooks JD, Boice JD, Jr, Stovall M, Reiner AS, Bernstein L, John EM, Lynch CF, Mellemkjær L, Knight JA, Thomas DC, Haile RW, Smith SA, Capanu M, The WECARE Collaborative Group, Bernstein JL, Shore RE. Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in The WECARE Study. International Journal of Radiation Oncology, Biology, Physic 2011;(in press).

Brooks JD, John EM, Mellemkjaer L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE; The WECARE Study Collaborative Group, Bernstein JL, Bernstein L. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Research and Treatment 2012;131:571-580.

Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, Capanu M, Stovall M, Smith SA, Wei S, Shore RE, Boice, Jr. JD, Lynch CF, Mellemkjær L, Malone KE, Liang X, the WECARE Study Collaborative Group, Haile RW, Concannon P, Bernstein JL. Variants in activators and downstream targets of ATM, radiation exposure and contralateral breast cancer risk in the WECARE study. Human Mutation 2012;33:158-164.

Bruner DW, Hanisch LJ, Trotti A, Reeve BB, Schrag D, Sit L, Minasian L, O’Mara A, Denicoff A, Rowland J, Montello M, Geoghegan C, Abernethy A, Clauser S, Castro K, Mitchell S, Burke L, Trentacosti AM, Basch E. Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Translational Behavioral Medicine 2011;1:110-122.

Butte JM, Do RK, Shia J, Gönen M, D'Angelica MI, Getrajdman GI, Allen PJ, Fong Y, Dematteo RP, Klimstra DS, Jarnagin WR. Liver angiomyolipomas: A clinical, radiologic, and pathologic analysis of 22 patients from a single center. Surgery 2011;150:557-567.

Butte JM, Gönen M, Allen PJ, D'Angelica MI, Kingham TP, Fong Y, Dematteo RP, Blumgart L, Jarnagin WR. The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB: the office journal of the International Hepato Pancreato Biliary Association 2011;13:463-472.

Butte JM, Matsuo K, Gönen M, D'Angelica MI, Waugh E, Allen PJ, Fong Y, DeMatteo RP, Blumgart L, Endo I, De La Fuente H, Jarnagin WR. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. Journal of the American College of Surgeons 2011;212:50-61.

Bylund CL, Goytia EJ, D'Agostino TA, Bulone L, Horner J, Li Y, Kemeny M, Ostroff JS. Evaluation of a pilot communication skills training intervention for minority cancer patients. Journal of Psychosocial Oncology 2011;29:347-358.

Cahlon O, Brennan MF, Jia X, Qin LX, Singer S, Alektiar KM. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Annals of Surgery 2012;255:343-347.

Capanu M, Begg CB. Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method. Biometrics 2011;67:371-380.

Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL, The WECARE Study Collaborative Group, Begg CB. Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genetic Epidemiology 2011;35:389-397.

Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Zanzonico P, Smith-Jones P, Divgi CR, Pryma D, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg D, Gonen M, Panageas KS, Ritter G, Jungbluth A, Old LJ, Larson SM. I-124 huA33 antibody PET imaging of colorectal cancer. Journal of Nuclear Medicine 2011;52:1173-1180.

Carrier ER, Schneider E, Pham HH, Bach PB. Association between quality of care and the socio-demographic composition of physicians' patient panels: a repeat cross-sectional analysis. Journal of General Internal Medicine 2011;26:987-994.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. Journal of the American Medical Association 2011;305:2327-2334.

Cassileth BR, Van Zee KJ, Chan Y, Coleton MI, Hudis CA, Cohen S, Lozada J, Vickers AJ. A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema. Acupuncture in Medicine 2011;29:170-172.

Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch VW, Sima CS, Ladanyi M, Kris MG. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma - rationale for comprehensive mutation profiling. Molecular Cancer Theraputics 2012;[epub ahead of print].

Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical Cancer Research 2011;17:6298-6303.

Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The influence of UGT1A6 variants and aspirin use in a randomized trial of celeboxib for prevention of colorectal adenoma. Cancer Prevention Research 2012;5:61-72.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prevention Research 2011;4:1172-1180.

Chandran U, Bandera EV, Williams-King MG, Paddock L, Rodriguez-Rodriguez L, Lu S-E, Faulkner S, Pulick K, Olson SH. Adherence to the dietary guidelines for Americans and ovarian cancer risk. Cancer Causes Control 2011;22:563-571.

Chen J, Guo T, Zhang L, Qin LX, Singer S, Maki RG, Taguchi T, Dematteo R, Besmer P, Antonescu CR. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes & Cancer 2012;51:186-195.

Chen L-S, Saccone NL, Culverhouse RC, Bracci PM, Chen C-H, Dueker N, Han Y, Huang H, Jin G, Kohno T, Ma JZ, Przybeck TR, Sanders AR, Smith JA, Sung YJ, Wenzlaff AS, Wu C, Yoon D, Bergen AW, Chen Y-T, Cheng Y-C, Cho YS, David SP, Duan J, Eaton C, Furberg H, Goate AM, Gu D, Hansen HM, Hartz S, Hu Z, Kim YJ, Kittner SJ, Levinson DF, Mosley TH, Payne TJ, Rao DC, Rice JP, TK, Schwantes-An T-H, Shete SS, Shi J, Spitz MR, Sun YV, Tsai F-J, Wang JC, Wrensch MR, Xian H, Gejman PV, He J, Hunt SC, Kardia SL, Li MD, Lin D, Mitchell BD, Park T, Schwartz AG, Shen H, Wiencke JK, Wu J-Y, Yokota J, Amos CI, Bierut LJ. Smoking and genetic risk variation across populations of European, Asian and African-American Ancestry - A meta-analysis of chromosome 15q25. Genetic Epidemiology 2011;(in press).

Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology 2012;7:434-442.

Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T Cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biology of Blood and Marrow Transplantation 2011;17:1708-1713.

Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Research and Treatment 2011;[epub ahead of print].

Correa D, Shi W, Abrey L, DeAngelis L, Omuro A, Deutsch M, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology 2011;14:101-108.

Crago AM, Socci ND, DeCarolis P, O’Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clinical Cancer Research 2012; [epub ahead of print].

Damast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases. International Journal of Radiation Oncology, Biology, Physics 2011;81:819-826.

D'Angelica M, Ammori J, Gönen M, Klimstra DS, Low PS, Murphy L, Weiser MR, Paty PB, Fong Y, Dematteo RP, Allen P, Jarnagin WR, Shia J. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology 2011;24:1221-1228.

D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Annals of Surgical Oncology 2011;18:1096-1103.

D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. Journal of Clinical Oncology 2011;29:2066-2070.

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European Urology 2011;60:897-904.

Danise EJ, Furberg H, Afari N, Buchwald D, Edwards K, Goldberg J, Schur E, Sullivan PF. Conditions comorbid with chronic fatigue in a population-based sample. Psychosomatics 2012;53:44-50.

Davis-Dao C, Koh CJ, Hardy BE, Chang A, Kim SS, De Filippo R, Hwang A, Pike MC, Carroll JD, Coetzee GA, Vandenberg D, Siegmund K, Cortessis VK. Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. Journal of Clinical Endocrinology & Metabolism 2011;[epub ahead of print].

Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, Pike MC, Bernstein L, Cortessis VK. Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiology Biomarkers and Prevention 2011;20:1156-1170.

Davis-Dao CA, Siegmund KD, Vandenberg DJ, Skinner EC, Coetzee GA, Thomas DC, Pike MC, Cortessis VK. Heterogeneous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types. Carcinogenesis 2011;32:1238-1243.

de Gonzalez AB, Kim KP, Landsdorp-Vogelaar I, Rutter CM, Smith-Bindman R, Yee J, Kuntz KM, van Ballegooijen M, Zauber AG, Berg CD. Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. American Journal of Roentgenology 2011;196:816-823.

Deng G, Kurtz RC, Vickers A, Lau N, Yeung KS, Shia J, Cassileth B. A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. Journal of Ethnopharmacology 2011;136:83-87.

Deodhar A, Dickfeld T, Single GW, Hamilton WC Jr, Thornton RH, Sofocleous CT, Maybody, Gönen M, Rubinsky B, Solomon SB. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR American Journal of Roentgenology 2011;196:W330-335.

Devlin SM, Thomas E, Emerson SS. Robustness of approaches to ROC curve modeling under misspecification of the underlying probability model. Communications in Statistics - Theory and Methods 2011; (in press).

Dickson MA, Carvajal RD, Merrill AH, Gönen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clinical Cancer Research 2011;17:2484-2492.

DuHamel K, Li Y, Rakowski W, Samimi P, Jandorf L. Validity of the process of change for colorectal cancer screening among African Americans. Psychological Assessment. Annals of Behavioral Medicine 2011;41:271-283.

Dusza SW, Halpern AC, Satagopan JM, Oliveria SA, Weinstock MA, Scope A, Berwick M, Geller AC. Prospective study of sunburn and sun behavior patterns during adolescence. Pediatrics 2012;129:309-317.

Dworkin RH, Turk DC, Basch E, Berger A, Cleeland C, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Markman J, Porter L, Raja SN, Ross E, Todd K, Wallace M, Woolf CJ. Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. Pain 2011;152:1705-1708.

Edwards-Bennett SM, Jacks LM, McCormick B, Zhang Z, Azu M, Ho A, Powell S, Brown C. Patterns of utilization of adjuvant radiation therapy and outcomes in black women after breast conservation at a large multidisciplinary cancer center. International Journal of Radiation Oncology, Biology, Physics 2011;80:1102-1108.

Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2011;[epub ahead of print].

Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and outcomes of breast cancer in women with and without a history of radiation for hodgkin’s lymphoma: a multi-institutional, matched cohort study. Journal of Clinical Oncology 2011;29:2466-2473.

Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genetic Medicine 2011;13:853-860.

Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: Barriers to breast cancer screening. Cancer Causes Control 2012;23:45-50.

Elston RC, Satagopan JM, Sun S. Statistical Human Genetics: Methods and Protocols (Methods in Molecular Biology). Springer, New York 2012 edition (February 29, 2012).

Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O'Reilly EM. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2011;[epub ahead of print].

Etzel CJ, Bach PB. Estimating individual risk for lung cancer. Seminars in Respiratory and Critical Care Medicine 2011;32:3-9.

Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA. Breast cancer methylomes establish an epigenomic foundation for metastasis. Science Translational Medicine 2011;3:75ra25.

Feifer AH, Elkin EB, Lowrance WT, Denton B, Jacks L, Yee DS, Coleman JA, Laudone VP, Scardino PT, Eastham JA. Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer 2011;117:3933-3942.

Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer 2012;118:981-986.

Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG. 500 Patients with merkel cell carcinoma evaluated at a single institution. Annals of Surgery 2011;254:465-473; discussion 473-475.

Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG. Recurrence after complete resection and selective use of adjuvant therapy for stage 1-3 Merkel cell carcinoma. Cancer 2011;[epub ahead of print].

Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, Singer S, Brennan MF. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Annals of Surgical Oncology 2011;18:328-336.

Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. British Journal of Cancer 2011;104:1840-1847.

Figueiredo JC, Brooks JD, Conti DV, Poynter JN, Teraoka SN, Malone KE, Bernstein L, Lee WD, Duggan DJ, Siniard A, Concannon P, Capanu  M, Lynch CF, Olsen JH, Haile RW, Bernstein JL. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: Potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Research and Treatment 2011;127:819-829.

Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, Gönen M, Schöder H, Humm JL, Scher HI, Larson SM. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. Journal of Nuclear Medicine 2011;52:1727-1732.

Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D, Stambuk H, Haque S, Pfister DG. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Research 2011;31:249-253.

Fury MG, Drobnjak M, Sima CS, Asher M, Shah J, Lee N, Carlson D, Wendel HG, Pfister DG. Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma. Head Neck 2011;33:1340-1345.

Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2011;117:795-801.

Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N, Pfister D. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemotherapy Pharmacology 2011;[epub ahead of print].

Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 2011;117:4125-4131.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment 2012;131:111-116.

Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. European Urology 2011;60:344-349.

Gardner GJ, Baser R, Brady MF, Bristow RE, Markman M, Spriggs D, Thaler HT. CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecologic Oncology 2012;124:216-220.

Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Thompson WD, Bernstein JL. Risk factors by molecular subtypes of breast cancer among a population-based study of women 56 years or younger. Breast Cancer Research and Treatment 2011;130:587-597.

Gaujoux S, Brennan MF, Gönen M, D'Angelica MI, DeMatteo R, Fong Y, Schattner M, DiMaio C, Janakos M, Jarnagin WR, Allen PJ. Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. Journal of American College of Surgeons 2011;212:590-600; discussion 600-603.

Gaujoux S, Tang L, Klimstra D, Gönen M, Brennan MF, D'Angelica M, Dematteo R, Fong Y, Jarnagin W, Allen PJ. The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis. Surgery 2011;[epub ahead of print].

Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical Cancer Research 2011;17:2493-2501.

Gerst S, Hann LE, Li D, Gonen M, Tickoo S, Sohn MJ, Russo P. Evaluation of renal masses with contrast-enhanced ultrasound: initial experience. AJR American Journal of Roentgenology 2011;197:897-906.

Ghosh P, Nathoo F, Gönen M, Tiwari RC. Assessing noninferiority in a three-arm trial using the Bayesian approach. Statistics in Medicine 2011;30:1795-808.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. European Respirator Journal 2012;39:366-372.

Gobble RM, Qin LX, Brill ER, Angeles CV, Ugras S, O'Connor RB, Moraco NH, Decarolis PL, Antonescu CR, Singer S. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Research 2011;71:2697-2705.

Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F, Castro-Malaspina H, Giralt S, Jakubowski AA, Koehne G, van den Brink MR, Young JW, Zhang Z, Papadopoulos EB, Perales MA. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma 2012;[epub ahead of print].

Goldfarb S, Baron S, Lindau S. Female Sexuality Women and Health, Second Edition. Ed. Goldman M, Troisi R, and Rexrode K. NIH: 2011;(in press).

Goldfarb S, Carter J, Dickler M. Addressing sexual function after breast cancer therapy. Coping: September/October 2011.

Goldfarb S, Hudis C, Dickler M. Bevacizumab in metastatic breast cancer: when may it be used? Therapeutic Advances in Medical Oncology 2011;3:85-93.

Goldfarb S. The impact of breast cancer and its treatment on sexuality. Journal of Sexual Medicine 2011;(in press).

Goldfarb S.Venlafaxine and clonidine for treatment of hot flashes in women with breast cancer. Journal of Clinical Oncology podcast: September 12th, 2011.

Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gönen M, Kuk D, Weiser M, Saltz L, Schrag D, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. European Radiology 2011;[epub ahead of print].

Gönen M. Bayesian enrichment strategies for randomized discontinuation trials. Biometrics 2011;[epub ahead of print].

Gönen M. Bias, biostatistics, and prognostic factors. Journal of Thoracic Oncology 2011;6:Suppl 3:S1705-1709.

González SJ, Wong J, González L, Brader P, Zakowski M, Gönen M, Fong Y, Strong VE. Novel handheld PET probes provide intraoperative localization of PET-avid lymph nodes. Surgical Endoscopy 2011;25:3214-3221.

Goulart JM, Oliveria SA, Levitt J. Safety during dermatologic procedures and surgeries: a survey of resident injuries and prevention strategies. Journal of the American Academy of Dermatology 2011; 65:648-650.

Govindarajan A, Gönen M, Weiser MR, Shia J, Temple LK, Guillem JG, Paty PB, Nash GM. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. Journal of Clinical Oncology 2011;29:4568-4573.

Gucalp A, Sparano J, Caravelli J, Santamauro, Patil S, Abbruzzi A, Pelligrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis CA, Traina TA. Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer. Clinical Breast Cancer 2011;11:306-311.

Guest RS, Baser R, Li Y, Scardino PT, Brown AE, Kissane DW. Cancer surgeons' distress and well-being, I: the tension between a culture of productivity and the need for self-care. Annals of Surgical Oncology 2011;18:1229-1235.

Guest RS, Baser R, Li Y, Scardino PT, Brown AE, Kissane DW. Cancer surgeons' distress and well-being, II: modifiable factors and the potential for organizational interventions. Annals of Surgical Oncology 2011;18:1236-1242.

Gupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuro-radiology2011;[epub ahead of print].

Gupta A, Young RJ, Sood S, Karimi S, Zhang Z, Mo Q, Gutin PH, Holodny AI, Lassman AB. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. American Journal of Neuroradiology 2011;32:1301-1306.

Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A, Gönen M, Zanzonico PB, Fong Y, Szalay AA. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. Journal of Translational Medicine 2011;9:36.

Haeno H, Gönen M, Davis MB, Herman JM, Iacobuzio-Donahue JA, Michor FM. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012;148:362-375.

Halpern NA, Pastores SM, Chou JF, Chawla S, Thaler HT. Advance directives in an oncologic intensive care unit: a contemporary analysis of their frequency, type, and impact. Journal of Palliative Medicine 2011;14:483-489.

Hambly NM, Gönen M, Gerst SR, Li D, Jia X, Mironov S, Sarasohn D, Fleming SE, Hann LE. Implementation of evidence-based guidelines for thyroid nodule biopsy: a model for establishment of practice standards. AJR American Journal of Roentgenology 2011;196:655-660.

Hanash AM, Kappel LW, Yim NL, Nejat RA, Goldberg GL, Smith OM, Rao UK, Dykstra L, Na IK, Holland AM, Dudakov JA, Liu C, Murphy GF, Leonard WJ, Heller G, van den Brink MR. Abrogation of donor T cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011;118:446-455.

Hartz SM, Short S, Saccone NL, Culverhouse R, Chen LS, Schwantes-An T, Coon H, Han Y, Stephens SH, Sun J, Chen X,  Ducci F, Dueker N, Franceschini N, Frank J, Geller F, Guðbjartsson D, Hansel N, Jiang C, Keskitalo-Vuokko K, Liu J, Lyytikäinen L, Michel M, Rawal R, Rosenberger A, Scheet P, Shaffer JR, Teumer A, Thompson JR, Vink JM, Vogelzangs N, Wenzlaff A, Wheeler W, Xiangjun X, Yang BZ, Aggen SH, Balmforth A, Baumeister S, Beaty T, Bennett S, Bergen A, Boyd H, Broms U, Campbell H, Chatterjee N, Chen J, Cheng YC, Cichon S, Couper D, Cucca F, Dick D, Foroud T, Furberg H, Giegling I, Gu F, Hall AS, Hällfors J, Han S, Hartmann AM, Hayward C, Heikkilä K, Hewitt JK, Hottenga JJ, Jensen M, Jousilahti P, Kaakinen M, Kittner S, Konte B, Korhonen B, Landi MT, Laatikainen T, Leppert M, Levy SM, Mathias R, McNeil DW, Medland S, Montgomery G, Muley T, Murray T, Nauck M, North K, Pergadia M, Polasek O, Ramos E, Ripatti S, Risch A, Ruczinski I, Rudan I, Salomaa V, Schlessinger D, Styrkársdóttir U, Terracciano A, Uda M, Willemsen G, Wu X, Abecasis G, Barnes K, Bickeböller H, Boerwinkle E, Boomsma DI, Caporaso N, Duan J, Edenberg HJ, Francks C, Gejman PV, Gelernter J, Grabe HJ, Hops H, Jarvelin MR, Jorma V, Kähönen M, KendlerKS, Lehtimäki T, Levinson DF, Marazita ML, Marchini J, Melbye M, Mitchell B, Murray JC, Nöthen MM, Penninx BW, Raitakari O, Rietschel M, Rujescu D, Samani NJ, Sanders AR, Schwartz A Shete S, Shi J, Spitz M, Stefansson K, Swan G, Thorgeirsson T, Völzke H, Wei Q, Wichmann HE, Amos C, Breslau N, Cannon D, Ehringer M, Grucza R, Hatsukami D, Heath A, Johnson E, Kaprio J, Madden P, Martin NG, Stevens V, StitzelJA,  Weiss RB, Kraft P, Bierut LJ. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Archives of General Psychiatry 2011;(in press).

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA. Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Research and Treatment 2011;130:619-626.

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. American Journal of Managed Care 2011;17(5 Spec No):e174-181.

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. Journal of Oncology Practice 2011;7(3 Suppl):e1s-7s.

Hay J, Kaphingst KA, Baser R, Li Y, Hesley-Alford S, McBride CM. Skin cancer concerns and genetic risk information-seeking in primary care. Public Health Genomics 2012;15:57-72.

Heller G. A measure of explained risk in the proportional hazards model. Biostatistics 2011;[epub ahead of print].

Heller G. Proportional hazards regression with interval censored data using an inverse probability weight. Lifetime Data Analysis 2011;17:373-385.

Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer 2011;[epub ahead of print].

Ho AY, Cordeiro P, Disa J, Mehrara B, Wright J, Van Zee KJ, Hudis C, McLane A, Chou JC, Zhang Z, Norton L, Powell S, McCormick B. Long-term outcomes in breast cancer patients undergoing immediate two-stage expander/implant reconstruction and postmastectomy radiation. Cancer 2011;[epub ahead of print].

Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A. YKL-40 and MMP-9 as serum markers for patients with primary CNS lymphoma. Annals of Neurology 2011;70:163-169.

House MG, Kemeny NE, Gönen M, Fong Y, Allen PJ, Paty PB, Dematteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Annals of Surgery 2011;254:851-856.

Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception 2011;(in press).

Huguet F, Wu AJ, Zhang Z, Shi W, O’Reilly EM, Winston CB, Reidy DL, Ho AY, Allen P, Goodman KA. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves high rate of R0 resection and prolonged survival. Journal of Clinical Oncology 2011;[epub ahead of print].

Hwang S, Lefkowitz R, Landa J, Zheng J, Moskowitz CS, Maybody M, Hameed M, Panicek DM. Percutaneous CT-guided bone biopsy: diagnosis of malignancy in lesions with initially indeterminate biopsy results and CT features associated with diagnostic or indeterminate results. American Journal of Roentgenology 2011;197:1417-1425.

Hyman D, Zhou Q, Iasonos A, Grisham R, Arnold AG, Phillips MF, Bhatia J, Levine D, Aghajanian C, Barakta RR, Spriggs DR, Kauff ND. Improved survival for BRCA2, but not BRCA1, carriers with epithelial ovarian cancer. Cancer;(in press).

Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology 2011;123:196-199.

Iasonos A, O’Quigley J. Continual reassessment and related designs in dose finding studies. Statistics in Medicine 2011;30:2057-2061. Editorial.

Iasonos A, Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011;30:2117-2129.

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Identifying clinical improvement in consolidation single-arm phase II trials in patients with ovarian cancer in second or greater clinical remission. International Journal of Gynecological Cancer 2012;22:63-69.

Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clinical Trials 2011;8:370-379.

Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117:1409-1414.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2011;[epub ahead of print].

Ito H, Ito K, D’Angelica M, Gönen M, Klimstra D, Allen P, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Annals of Surgery 2011;254:320-325.

Ito K, Blinder V, Elkin E. Cost-effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Journal of Clinical Oncology. 2011;(in press).

Ito K, Ito H, Kemeny NE, Gönen M, Allen PJ, Paty PB, Fong Y, Dematteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Annals of Surgical Oncology 2011;[epub ahead of print].

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-Oncology 2011;13:1244-1251.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. Journal of Neuro-Oncology 2011;105:607-612.

Jardines L, Goyal S, Fisher P, Weitzel J, Royce M, Goldfarb S. Breast Cancer Overview. Cancer Management: A Multidisciplinary Approach 14th Edition. UBM Medica 2011.

Jiang X, Castelao JE, Yuan JM, Stern MC, Conti DV, Cortessis VK, Pike MC, Gago-Dominguez M. Cigarette smoking and subtypes of bladder cancer. International Journal of Cancer 2012;130:896-901.

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Journal of Thoracic Oncology 2011;6:1128-1131.

Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, Howarth K, Ballereau S, Hodgson SV, Zauber AG, Bertagnolli M, Midgley R, Campbell H, Kerr D, Dunlop MG, Tomlinson IP. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 2012;61:248-254.

Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD, Adusumilli PS. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Modern Pathology 2012;25:260-271.

Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. Journal of Thoracic Oncology 2011;6:896-904.

Kalinsky K, Heguy A, Bhanot U, Patil S, Moynahan ME. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment 2011;129:635-643.

Karakousis GC, Singer S, Zheng J, Gönen M, Coit D, Dematteo RP, Strong VE. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Annals of Surgical Oncology 2011;18:1599-1605.

Karanicolas PJ, Elkin EB, Jacks LM, Atoria CL, Strong VE, Brennan MF, Coit DG. Staging laparoscopy in the management of gastric cancer: a population-based analysis. Journal of the American College of Surgeons 2011;213:644-651.

Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, D'Angelica MI. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. Journal of Clinical Oncology 2011;29:884-889.

Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153-159.

Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 2011;[epub ahead of print].

Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, Panageas K, Livingston PO. Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunology Immunotherapy 2011;60:621-627.

King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Annals of Surgery 2011;254:2-7.

King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of Clinical Oncology 2011;29:2158-2164.

King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement on breast MRI and breast cancer risk. Radiology 2011;260:50-60.

Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallström P, Vickers AJ, Lilja H. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. European Urology 2012;61:471-477.

Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z, Jia X, Shi W, Zelefsky MJ. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2011;79:713-718.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA. A Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of Clinical Oncology 2011;29:4662-4668.

Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2011;81:915-922.

Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunology and Immunotherapy 2011;61:9-18.

Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Medical Decision Making 2011;31:530-539.

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Annals of Internal Medicine 2011;155:69-79.

Lampen-Sachar K, Zhao B, Zheng J, Moskowitz CS, Schwartz LH, Zakowski MF, Rizvi NA, Kris MG, Ginsberg MS. Correlation between tumor measurement on computed tomography and resected specimen size in lung adenocarcinomas. Lung Cancer 2012;75:332-335.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology 2011;13:649-659.

Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Research 2011;71:2871-2881.

Li Y, Baser R. Using R and WinBUGS to fit a generalized partial credit model for developing and evaluating patient-reported outcomes assessments. Statistics in Medicine 2011;(in press).

Li Y, Schwartz C. Data mining for response shift patterns in multiple sclerosis patients using recursive partitioning tree analysis. Quality of Life Research 2011;20:1543-1553.

Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210-1219.

Lindau S, Sandbo S, Goldfarb S, Dickler M. Sexuality, Breast Cancer and Aging: A Multidisciplinary and Life Course Perspective. Cancer and Sexuality. Ed. Mulhall JP, Goldstein I, Incrocci L, Rosen R. Springer 2011.

Lipitz-Snyderman A, Needham DM, Colantuoni E, Goeschel CA, Marsteller JA, Thompson DA, Berenholtz SM, Lubomski LH, Watson S, Pronovost PJ.  How long can intensive care units maintain zero central line-associated bloodstream infections?  Archives of Internal Medicine 2011;171:856-858.

Lipitz-Snyderman A, Steinwachs D, Needham DM, Colantuoni E, Morlock LL, Pronovost PJ.  Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay. BMJ 2011; 2-11; 342:d219.

Liu L, Zhang J, Wu AH, Pike MC, Deapen D. Invasive breast cancer incidence trends by detailed race/ethnicity and age. International Journal of Cancer 2012;130:395-404.

Lok BH, Khan S, Mutter R, Liu J, Fields R, Pulitzer M, Shi W, Zhang Z, Kraus D, Pfister D, Busam KJ, Brownell I, Lee N. Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer 2011;[epub ahead of print].

Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. International Journal of Radiation Oncology, Biology, Physics 2011;[epub ahead of print].

Lowrance WT, Eastham JA, Yee DS, Laudone VP, Denton B, Scardino PT, Elkin EB. Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis. Cancer 2011;[epub ahead of print].

Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, Atoria CL, Zelefsky MJ, Scher HI, Scardino PT, Eastham JA. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Internation 2011;[epub ahead of print].

Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, Jarnagin WR, Kurtz RC. Feasibility and yield of screening in relatives from familial pancreatic cancer families. American Journal of Gastroenterology 2011;106:946-954.

Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K, Setiawan VW, Rebbeck TR, Prescott J, Orlow I, O'Mara T, Olson SH, Narod SA, Matsuno RK, Lissowska J, Liang X, Levine DA, LeMarchand L, Kolonel LN, Henderson BR, Garcia-Closas M, Doherty JA, De Vivo I, Chen C, Brinton LA, Akbari MR, Australian National Endometrial Cancer Study Group, Australian National Endometrial Cancer Study Group, Goodman MT. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One 2011;8:6:e16756.

Lurie G, Wilkens LR, Thompson PJ, Shvetsov YB, Matsuno RK, Carney ME, Palmieri RT, Wu AH, Pike MC, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Whittemore AS, McGuire V, Sieh W, Pharoah PD, Song H, Gronwald J, Jakubowska A, Cybulski C, Lubinski J, Schildkraut JM, Berchuck A, Krüger Kjær S, Høgdall E, Fasching PA, Beckmann MW, Ekici AB, Hein A, Chenevix-Trench G, Webb PM, Beesley J, Australian Ovarian Cancer Study Group, Australian Cancer Study Group, Goodman MT, Ovarian Cancer Association Consortium. Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS One 2011;6:e20703.

Maithel SK, Gönen M, Ito H, Dematteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, D'Angelica MI. Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery 2012;151:162-170.

Maker AV, Butte JM, Oxenberg J, Kuk D, Gönen M, Fong Y, Dematteo RP, D'Angelica MI, Allen PJ, Jarnagin WR. Is port site resection necessary in the surgical management of gallbladder cancer? Annals of Surgical Oncology 2012;19:409-417.

Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ. Cyst fluid interleukin-1b levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clinical Cancer Research 2011;17:1502-1508.

Mandelcorn-Monson R, Marrett L, Kricker L, Armstrong B, Orlow I, Goumas C,  Paine S , Stefano Rossof, Thomas N,  Millikan RC, Pole JD, Cotignola J, Rosen C, Kanetsky P, Lee-Taylor J, Begg CB, Berwick M. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiology 2011;35:e105-110.

Mankoo PK, Shen R, Schultz N, Levine DA, Sander C. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS One 2011;6:e24709.

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. Journal of Clinical Investigation 2011;121:2723-2735.

Marti JL, Dauer LT, Stempel M, Patil S, Kaplan JB, Montgomery LL. Cumulative imaging radiation exposure following breast-conservation therapy. Annals of Surgical Oncology 2011;18:104-108.

McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 2011;117:5461-5468.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical Cancer Research 2011;17:3398-3407.

McCormack V, Hung RJ, Brenner DR, Bickeböller H, Rosenberger A, Muscat JE, Lazarus P, Tjønneland A, Friis S, Christiani DC, Chun E-M, LeMarchand L, Rennert G, Rennert HS, Andrew AS, Orlow I, Park B, Boffetta P, Eric J Duell EJ. Aspirin and NSAID use in lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2011;22:1709-1720.

Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, Zanzonico P, Smith-Jones P, Larson SM. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. Journal of Controlled Release 2011;149:292-298.

Meehan CP, Fuqua Iii JL 3rd, Reiner AS, Moskowitz CS, Schwartz LH, Panicek DM. Prognostic significance of adrenal gland morphology at CT in patients with three common malignancies. British Journal of Radiology 2011;[epub ahead of print].

Mirkin JN, Bach PB. Outcome-blinded peer review. Archive of Internal Medicine 2011;171:1213-1214;author reply 1214.

Mironov O, Ishill NM, Mironov S, Vargas HA, Zheng J, Moskowitz CS, Sonoda Y, Papas RS, Chi DS, Hricak H. Pleural effusion detected at CT prior to primary cytoreduction for Stage III or IV ovarian carcinoma: effect on survival. Radiology 2011;258:776-784.

Mo Q. A fully Bayesian hidden ising model for ChIP-seq data analysis. Biostatistics 2012;13:113-128.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research 2011;17:5132-5139.

Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011;[epub ahead of print].

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. American Journal of Clinical Oncology 2011;34:454-459.

Moroz MA, Huang R, Kochetkov T, Shi W, Thaler H, de Stanchina E, Gamez I, Ryan RP, Blasberg RG. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clinical Cancer Research 2011;17:3282-3292.

Morris P, Murphy C, Mallam D, Accordino M, Patil S, Howard J, Omur A, Beal K, Seidman AD, Hudis CA, Fornier M. Limited overall survival in patients with brain metastases from triple negative breast cancer. The Breast Journal 2011;(in press).

Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, DeAngelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary CNS lymphoma treated with immunochemoradiotherapy. Leukemia Lymphoma 2011;52:1891-1897.

Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clinical Cancer Research 2011;17:3490-3499.

Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal of Thoracic Oncology 2011[epub ahead of print].

Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, Arroyo CD, Brogi E, Morrow M, King TA. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Research and Treatment 2011;[epub ahead of print].

Morrogh M, Andrade VP, Patil AJ, Qin LX, Mo Q, Sakr R, Arroyo CD, Brogi E, Morrow M, King TA. Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole. Journal of Surgical Research 2011;[epub ahead of print].

Mosher CE, DuHamel KN, Lam J, Dickler M, Li Y, Massie MJ, Norton L. Randomized trial of expressive writing for distressed metastatic breast cancer patients. Psychology and Health 2011:1-13.

Moskowitz CS, Zabor EC, Jochelson M. Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. The Breast Journal 2011;(in press).

Movsas B, Vikram B, Hauer-Jensen M, Moulder J, Basch E, Brown SL, Kachnic LA, Dicker A, Coleman CN, Okunieff P. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clinical Cancer Research 2011;17:222-228.

Mukherjee S, Simon J, Bayuga S, Ludwig E, Orlow I, Viale A, Offit K, Kurtz RC,Olson SH, Klein RJ. Shared controls to improve the power of genome wide association studies. Human Heredity 2011;72:21-34.

Murali R, Goumas C, Fromm L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Kricker A, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK for the GEM Study Group. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Annals of Surgical Oncology 2011;[epub ahead of print].

Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, Hudis CA, Gemignani ML, Seidman AD. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer 2011;[epub ahead of print].

Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer 2012;118:518-527.

Nash GM, Row D, Weiss A, Shia J, Guillem JG, Paty PB, Gonen M, Weiser MR, Temple LK, Fitzmaurice G, Wong WD. A predictive model for lymph node yield in colon cancer resection specimens. Annals of Surgery 2011;253:318-322.

Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM, Kjær SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL, Ovarian Cancer Association Consortium, Australian Cancer Study (Ovarian Cancer) (ACS), Australian Ovarian Cancer Study Group (AOCS). Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertility and Sterility 2011; 95:40-45.

Neuman HB, Patil S, Fuzesi S, Wong WD, Weiser MR, Guillem JG, Paty PB, Nash GM, Temple LK. Impact of a temporary stoma on the quality of life of rectal cancer patients undergoing treatment. Annals of Surgical Oncology 2011;18:1397-1403.

Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Mędrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, Wang-Gohrke S, Doherty JA, Rossing MA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Beesley J, Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer), Gronwald J, Fasching PA, Chang-Claude J, Goodman MT, Chenevix-Trench G, Berchuck A, Pearce CL, Whittemore AS, Menon U, Pharoah PD, Gayther SA, Ramus SJ, Ovarian Cancer Association Consortium. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer 2011;128:2063-2074.

O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H; on behalf of the Trans-Atlantic Prostate Group. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. International Journal of Cancer 2011;128:2373-2381.

Oliveria SA, Heneghan MK, Cushman LF, Ughetta EA, Halpern AC. Skin cancer screening by dermatologists, family practitioners, and internists: barriers and facilitating factors. Archives of Dermatology 2011;147:39-44.

Oliveria SA, Shuk E, Hay JL, Heneghan M, Goulart JM, Panageas K, Geller AC, Halpern AC. Melanoma survivors: health behaviors, surveillance, psychosocial factors, and family concerns. Psycho-oncology 2011;(in press).

Olson SH, Atoria CL, Cote ML, Cook LS, Rastogi R, Soslow RA, Brown CL, Elkin EB. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiology Biomarkers and Prevention 2011;(in press).

Olson SH, Layne TM, Simon JA, Ludwig E, O'Reilly E, Allen PJ, Kurtz RC. Studying cancer in minorities: a look at the numbers. Cancer 2011;117:2762-2769.

Olson SH. Medical conditions and risk of pancreatic cancer. Molecular Carcinogenesis 2011;(in press).

O'Quigley J, Iasonos A. Dose finding designs based on the continual reassessment method.  Handbook of Statistics in Clinical Oncology ed. by John Crowley, Маrcеl Dеkkеr 2011.

Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M; for the GEM Study Group. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. International Journal of Cancer 2012;130:405-418.

Ostrovnaya I, Nicolae D. Estimating the proportion of true null hypotheses under dependence. Statistica Sinica 2011;(in press).

Ostrovnaya I, Seshan VE, Olshen AB, Begg CB. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011;27:1698-1699.

Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research 2011;17:1616-1622.

Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clinical Cancer Research 2011;17:6322-6328.

Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, Riely GJ. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. Journal of Clinical Oncology 2011;29:3114-3119.

Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Journal of Clinical Oncology 2011;29:2046-2051.

Paik PK, James LP, Riely GJ, Azzoli CG, Miller VA, Ng KK, Sima CS, Heelan RT, Kris MG, Moore E, Rizvi NA. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane(®)) given as a two-hour infusion. Cancer Chemotherapy Pharmacology 2011;68:1331-1337.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Oligodendroglioma: Initial treatment patterns over time. Neuro-Oncology 2011;(in press).

Panageas KS, Sima CS, Liberman L, Schrag D. Use of high technology imaging for surveillance of early stage breast cancer. Breast Cancer Research and Treatment 2011;131:663-670.

Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248-1254.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology 2011;22:295-300.

Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G, AOCS/ACS Study Group, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics 2011;20:2263-2272.

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA, Ovarian Cancer Association Consortium. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clinical Cancer Research 2011;17:3742-3750.

Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biology and Blood Marrow Transplantation 2011;17:1316-1326.

Qi J, Shukla-Dave A, Fong Y, Gönen M, Schwartz LH, Jarnagin WM, Koutcher JA, Zakian KL. (31) P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization. Journal of Magnetic Resonance Imaging 2011;34:336-344.

Quintana MA, Bernstein JL, Thomas DC, Conti DV. Incorporating model uncertainty in detecting rare variants: the Bayesian Risk Index. Genetic Epidemiology 2011;35:638-649.

Raman T, Roistacher N, Liu J, Zhang H, Shi W, Thaler HT, Amar D. Preoperative left atrial dysfunction and risk of postoperative atrial fibrillation complicating thoracic surgery. Journal of Thoracic and Cardiovascular Surgery 2012;143:482-487.

Reiner AS, Jacks LM, Van Zee KJ, Panageas KS. A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men. Breast Cancer Research and Treatment 2011;130:301-306.

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of Thoracic Oncology 2011;6:28-31.

Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathology 2011;24:1348-1359.

Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clinical Cancer Research 2011;17:3500-3506.

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchock JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clinical Cancer Research 2011;17:1984-1997.

Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). Journal of Pain and Symptom Management 2012;43:205-217.

Rosen A, Balagula Y, Goldfarb S, Lacouture M. Dermatologic adverse events during treatment. In Principles and Practice of Palliative Care and Supportive Oncology. 2011;(in press).

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics 2011;42:978-984.

Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical Colorectal Cancer 2011;[epub ahead of print].

Salz T, Brewer NT. Direct-to-consumer genomewide profiling. [Letter] New England Journal of Medicine. 2011;364:2074.

Salz T, DeFrank JT, Brewer NT. False positive mammograms in Europe: do they affect reattendance? Breast Cancer Research and Treatment 2011;127:229-231.

Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and practice. CA: A Cancer Journal for Clinicians 2012; [epub ahead of print].

Sandhu JS, Maschino AC, Vickers AJ. The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience. European Urology 2011;60:1285-1290.

Sarkaria IS, Bains MS, Sood S, Sima CS, Reuter VE, Flores RM, Motzer RJ, Bosl GJ, Rusch VW. Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at Memorial Sloan Kettering Cancer Center. Journal of Thoracic Oncology 2011;6:1236-1241.

Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, Pietanza MC, Park BJ, Travis WD, Rusch VW. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Annals of Thoracic Surgery 2011;92:1180-1186; discussion 1186-1187.

Satagopan JM, Zhou Q, Oliveria SA, Dusza SW, Weinstock MA, Berwick M, Halpern AC. Properties of preliminary test estimators and shrinkage estimators for evaluating multiple exposure – Application questionnaire data from the SONIC study. Journal of the Royal Statistical Society Series C, Applied Statistics 2011;60:619-632.

Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biology of Blood and Marrow Transplantation 2011;17:1460-1471.

Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. Journal of Experimental Medicine 2011;208:1799-1807.

Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G. Randomized open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of Clinical Oncology 2011;29:2191-2198.

Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. Journal of Clinical Oncology 2011;29:3695-3704.

Schwartz J, Humm JL, Gönen M, Kalaigian H, Schoder H, Larson SM, Nehmeh SA. Repeatability of SUV measurements in serial PET. Medical Physics 2011;38:2629-2638.

Schwartz LH, Panicek DM, Berk AR, Li Y, Hricak H. Improving communication of diagnostic radiology findings through structured reporting. Radiology 2011;260:174-181.

Scope A, Dusza SW, Marghoob AA, Satagopan JM, Braga C, Tavoloni J, Psaty EL, Weinstock MA, Oliveria SA, Bishop M, Geller AC, Halpern AC. Clinical and dermoscopic stability and volatility of melanocytic nevi in a population-based cohort of children in Framingham school system. Journal of Investigative Dermatology 2011;131:1615-1621.

Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS. An in vivo platform for tumor biomarker assessment. PLoS One 2011;6:e26722.

Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey Jr. JV, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu X, Spurdle AB, Strom BL, The Australian National Endometrial Cancer Study Group, Thompson PJ, Ursin G, Webb PM, Weiss N, Wentzensen N, Xiang Y, Yang HP, Yu H, Horn-Ross PL, De Vivo I. Age at last birth in relation to risk of endometrial cancer: Pooled analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology 2011;(in press).

Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, Rowan N, Sherman EJ, Fury MG, Pfister DG, Wong RJ, Shah JP, Kraus DH, Shi W, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan Kettering Cancer Center experience. International Journal of Radiation Oncology Biology Physics 2012; 82:291-298.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Journal of Clinical Oncology 2011;29:868-874.

Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Investigational New Drugs 2011;29:1475-1481.

Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gönen M. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. European Urology 2012;61:237-42.

Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive  bladder cancer and negative cytology: A decision-curve analysis. Cancer 2011;117:2892-2897.

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica 2011;50 Suppl 1:61-75.

Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, Il’yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Yang P, Vick NA, Wrensch M, Davis FG, McCarthy BJ, Leung EH, Davis C, Cheng R, Hosking FJ, Armstrong GN, Liu Y, Yu RK, Henriksson R, The Gliogene Consortium, Melin BS, Bondy ML. Genome-wide high-density SNP linkage search for glioma susceptibility loci-results from the Gliogene Consortium. Cancer Research 2011;71:7568-7575.

Shia J, Stadler Z, Weiser MR, Rentz M, Gonen M, Tang LH, Vakiani E, Katabi N, Xiong X, Markowitz AJ, Shike M, Guillem J, Klimstra DS. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? American Journal of Surgical Pathology 2011;35:447-454.

Shia J, Stadler Z, Weiser MR, Rentz M, Gönen M, Tang LH, Vakiani E, Katabi N, Xiong X, Markowitz AJ, Shike M, Guillem J, Klimstra DS. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: How reliable are biopsy samples? American Journal of Surgical Pathology 2011;35:447-454.

Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR, Levine DA. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecological Oncology 2011;121:444-450.

Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. Gynecologic Oncology 2011;120:480-484.

Shike M, Schattner M, Genao A, Grant W, Burke M, Zauber A, Russo L, Cuyjet V. Expanding colorectal cancer screening among minority women. Cancer 2011;117:70-76.

Shukla-Dave A, Lee NY, Jansen JF, Thaler HT, Stambuk HE, Fury MG, Patel SG, Moreira AL, Sherman E, Karimi S, Wang Y, Kraus D, Shah JP, Pfister DG, Koutcher JA. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head and neck squamous cell carcinoma patients with nodal metastases. International Journal of Radiation Oncology Biology Physics 2011;[epub ahead of print].

Sigel CS, Rudomina DE, Sima CS, Rekhtman N, Travis WD, Geisinger KR, Moreira AL. Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathology 2011;[epub ahead of print].

Silberstein JL, Vickers AJ, Power NE, Fine SW, Scardino PT, Eastham JA, Laudone VP. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer 2011;117:4855-4860.

Silberstein JL, Vickers AJ, Power NE, Parra RO, Coleman JA, Pinochet R, Touijer KA, Scardino PT, Eastham JA, Laudone VP. Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures. Journal of Endourology 2011;[epub ahead of print].

Smyth EC, Hsu M, Panageas KS, Chapman PB. Histology and outcomes of newly detected lung lesions in melanoma patients. Annals of Oncology 2011;[epub ahead of print].

Sofocleous CT, May B, Petre EN, Gonen M, Thornton RH, Alago W, Rizk NP, Dupuy DE, Solomon SB. Pulmonary thermal ablation in patients with prior pneumonectomy. AJR American Journal of Roentgenology 2011;196:W606-612.

Sofocleous CT, Petre EN, Gonen M, Brown KT, Solomon SB, Covey AM, Alago W, Brody LA, Thornton RH, D'Angelica M, Fong Y, Kemeny NE. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. Journal of Vascular and Interventional Radiology 2011;22:755-761.

Song TJ, Haddad D, Adusumilli P, Kim T, Stiles B, Hezel M, Socci ND, Gönen M, Fong Y. Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy. Cancer Gene Therapy 2012;19:38-48.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012;118:493-499.

Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, Offit K, Foulkes WD, Robson ME, Tischkowitz M. Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics 2011;48:523-525.

Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. European Journal of Clinical Investigation 2012;42:216-228.

Sun L, Song X, Zhang Z. Mean residual life models with time-dependent coefficients under right censoring. Biometrika 2011;[epub ahead of print].

Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Prognostic immune markers in non-small cell lung cancer. Clinical Cancer Research 2011;17:5247-5256.

Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunology Immunotherapy 2011;60:1721-1728.

Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. Journal of Thoracic Oncology 2011;6:762-767.

Swartz RJ, Schwartz C, Basch E, Cai L, Fairclough DL, McLeod L, Mendoza TR, Rapkin B; SAMSI psychometric program longitudinal assessment of patient-reported outcomes working group. The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. Quality of Life Research 2011;20:1159-1167.

Tal R, Jacks LM, Elkin E, Mulhall JP. Penile implant utilization following treatment for prostate cancer: Analysis of the SEER-Medicare database. The Journal of Sexual Medicine 2011;8:1797-1804.

Tang M, Gönen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011;118:1622-1631.

Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD Jr. Siniard A, Duggan D, Thomas DC, The WECARE Study Collaborative Group, Concannon P. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology (WECARE) study. Breast Cancer Research 2011;13:R114.

The Cancer Genome Atlas Research Network. Bell D et al. (Shen R is 230th author) Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.

Thornton RH, Ulrich R, Hsu M, Moskowitz CS, Reidy-Lagunes D, Covey AM, Brody LA, Robson PM, Sofocleous CT, Solomon SB, Getrajdman GI, Brown KT. Outcomes of patients undergoing  percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy. Journal of Vascular and Interventional Radiology 2012;23:89-95.

Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee M, Tavtigian S, Concannon P, Foulkes WD, Bernstein L, Bernstein JL, Begg CB. Rare germline mutations in PALB2 and breast cancer risk: A population-based study. Human Mutation 2012;[epub ahead of print].

Tonorezos ES, Vega GL, Sklar CA, Chou JF, Moskowitz CS, Mo Q, Church TS, Ross R, Janiszewski PM, Oeffinger KC. Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatric Blood & Cancer 2011;258:776-784.

van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM. Clarifying differences in natural history between models of screening: the case of colorectal cancer. Medical Decision Making 2011;31:540-549.

Van Zee KJ, Rudloff U, Brogi E, Patil S. Reply to C. Manzouni et al. Journal of Clinical Oncology 2011;e45-e46.

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 2011;261:487-498.

Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz CS, Udo K, Eastham J, Hricak H. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259:775-784.

Vargas HA, Akin O, Zheng J, Moskowitz C, Soslow R, Abu-Rustum N, Barakat RR, Hricak H. The value of MR imaging when the site of uterine cancer origin is uncertain. Radiology 2011;258:785-792.

Vickers A, Eastham J. What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public? Urologic Oncology 2011;29:118-123.

Vickers A, Savage C, Bianco F, Mulhall J, Sandhu J, Guillonneau B, Cronin A, Scardino P. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. European Urology 2011;59:317-322.

Vickers A. Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. European Urology 2011;60:392.

Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Medical Research Methodology 2011;11:13.

Vickers AJ, Gupta A, Savage C, Pettersson K, Dahlin A, Bjartell AS, Manjer J, Scardino PT, Ulmert D, Lilja H. A panel of kallikrein markers predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiology Biomarkers and Prevention 2011;20:255-261.

Vickers AJ, Lilja H. Predicting prostate cancer many years before diagnosis: how and why? World Journal of Urology 2011;[epub ahead of print].

Vickers AJ, Lilja H. Urological cancer: Time for another rethink on prostate cancer screening. Nature Reviews Clinical Oncology 2011;9:7-8.

Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdetection? Annual Review of Medicine 2012;63:161-170.

Vickers AJ, Savage CJ, Bianco FJ, Klein EA, Kattan MW, Secin FP, Guilloneau BD, Scardino PT. Surgery confounds biology: the predictive value of stage, grade and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. International Journal of Cancer 2011;128:1697-1702.

Vickers AJ, Sjoberg D, Basch E, Sculli F, Shouery M, Laudone V, Touijer K, Eastham J, Scardino PT. How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. European Urology 2012;61:284-289.

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. Journal of the National Cancer Institute 2011;103:462-469.

Vickers AJ. Great meaningless questions in urology: which is better, open, laparoscopic, or robotic radical prostatectomy? Urology 2011;77:1025-1026.

Vickers AJ. Making raw data more widely available. BMJ 2011;342:d2323.

Vickers AJ. On behalf of the study team Memorial Sloan Kettering Cancer Center. Re: An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. Journal of National Cancer Institute 2011;103:1635-1636.

Vickers AJ. Prediction models in cancer care. CA Cancer Journal of Clinicians 2011;[epub ahead of print].

Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? Journal of Clinical Oncology 2011;29:2951-2952.

Vickers AJ. Re: comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. Journal of the National Cancer Institute 2011;103:1134.

Vickers AJ. Surgical volumes and patient outcomes in urological oncology. AUA Update Series 2011;36:30.

Waters HR, Korn R, Colantuoni E, Berenholtz S, Goeschel CJ, Needham D, Pham JC, Lipitz-Snyderman A, Watson SR, Posa P, Pronovost PJ.  The business case for quality: economic analysis of the Michigan keystone patient safety program in ICUs.  American Journal of Medical Quality 2011;26:333-339.

Weber WP, Barry M, Stempel MM, Junqueira MJ, Eaton AA, Patil SM, Morrow M, Cody HS 3rd. A 10-year trend analysis of sentinel lymph node frozen section and completion axillary dissection for breast cancer: are these procedures becoming obsolete? Annals of Surgical Oncology  2012;19:225-232.

Weiser MR, Gönen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. Journal of Clinical Oncology 2011;29:4796-4802.

Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception 2011;[epub ahead of print].

Winawer SJ, Zauber AG. Incidence reduction following colonoscopic polypectomy. American Journal of Gastroenterology 2011;106:370.(Letter to editor).

Wu AH, Yu MC, Stanczyk FZ, Tseng CC, Pike MC. Anthropometric, dietary, and hormonal correlates of serum adiponectin in Asian American women. Nutrition and Cancer 2011; 63:549-557.

Xu YF, Wang GC, Zheng JH, Peng B. Partial cystectomy: Is it a reliable option for the treatment of bladder leiomyosarcoma? Canadian Urological Association Journal 2011;5:E11-13.

Yaligar J, Thakur SB, Bokacheva L, Carlin S, Thaler HT, Rizwan A, Lupu ME, Wang Y, Matei CC, Zakian KL, Koutcher JA. Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomedicine 2012;25:113-122.

Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology 2011;78:544-549.

Yee DS, Shariat SF, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU International 2011;108:502-507.

Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gönen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, Dematteo RP, Allen PJ, Jarnagin WR. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Annals of Surgical Oncology 2011;18:2192-2199.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology 2011;24:653-664.

Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011;76:1918-1924.

Young RJ, Lee V, Peck KK, Sierra T, Zhang Z, Jacks LM, Holodny AI. Diffusion tensor imaging and tractography of the corticospinal tract in the presence of enlarged virchow-robin spaces. Journal of Neuro-imaging 2011;[epub ahead of print].

Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli S, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences 2011;108:16723-16728.

Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long term prevention of colorectal cancer deaths. New England Journal of Medicine 2011 (in press).

Zelefsky MJ, Chou JF, Pei X, Yamada Y, Kollmeier M, Cox B, Zhang Z, Schechter M, Cohen GN, Zaider M. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan Kettering Cancer Center experience. Brachytherapy 2011;[epub ahead of print].

Zelefsky MJ, Housman DM, Pei X, Alicikus Z, Magsanoc JM, Dauer LT, St Germain J, Yamada Y, Kollmeier M, Cox B, Zhang Z. Incidence of secondary cancer development after high-dose IMRT and image-guided brachytherapy for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2011;[epub ahead of print].

Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. European Urology 2011;60:1133-1139.

Zelefsky MJ, Yamada Y, Pei X, Hunt M, Cohen G, Zhang Z, Zaider M. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011;77:986-990.

Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ. Risk-based prostate cancer screening. European Urology 2011;[epub ahead of print].

Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012;118:660-669.